A key tariff exemption considers a drug's origin to be where its Active Pharmaceutical Ingredient (API) was made. This allows companies to manufacture an API in the US, export it for final formulation, and then re-import the finished product tariff-free, offering a significant supply chain strategy to bypass import taxes.

Instead of immediately passing tariff costs to consumers, US corporations are initially absorbing the shock. They are mitigating the impact by reducing labor costs and accepting lower profitability, which explains the lag between tariff implementation and broad consumer inflation.

The recent tariff ruling does not affect all trading partners equally. Nations like Vietnam, with high exposure to the now-defunct IEPA tariffs, will see significant changes. In contrast, countries like South Korea, whose exports are mainly subject to other unaffected tariffs (e.g., Section 232), will see little impact.

Flexport CEO Ryan Peterson reveals that high tariffs incentivize foreign companies to under-declare goods' value. The U.S. uniquely allows imports without a local entity, meaning there's little recourse when fraud is discovered. This creates a significant competitive disadvantage for American companies that follow the rules.

Unlike large firms making US investment pledges for exemptions, smaller drug makers must rely on nuanced, capital-light tactics. These include unbundling costs to lower dutiable value, using duty drawback programs for re-exported goods, and leveraging foreign trade zones to survive high tariff rates without massive infrastructure spending.

The legal underpinnings of US tariffs are changing, moving from temporary IEPA authorities to more durable Section 301 and 232 investigations. Despite this complex legal transition, economists expect the aggregate effective tariff rate to remain roughly the same, stabilizing around 10% from a macro perspective.

The share of U.S. trade using a foreign 'importer of record' more than doubled from 9% to 20% since last April. This structure creates a significant incentive for tariff fraud by allowing overseas factories to potentially undervalue goods upon import.

Geopolitical shifts mean a company's country of origin heavily influences its market access and tariff burdens. This "corporate nationality" creates an uneven playing field, where a business's location can instantly become a massive advantage or liability compared to competitors.

Immediate tariff relief on consumer goods is minor (1-4%), but a significant opportunity exists after the 150-day temporary tariff period. If no new sector-specific tariffs are implemented, categories like apparel could experience a dramatic 16-17 percentage point tariff reduction, boosting purchasing power.